Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.


Journal

Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464

Informations de publication

Date de publication:
24 01 2020
Historique:
received: 25 09 2019
accepted: 26 12 2019
entrez: 26 1 2020
pubmed: 26 1 2020
medline: 9 6 2021
Statut: epublish

Résumé

Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clinical management of patients, also because the molecular mechanisms behind therapy resistance are not yet fully understood. In the present study, we therefore aimed to identify novel targets to intervene with therapy resistance using gene expression analysis of PCa co-culture spheroids where PCa cells are grown in the presence of cancer-associated fibroblasts (CAFs) and which have been previously shown to be a reliable model for antiandrogen resistance. Gene expression changes of co-culture spheroids (LNCaP and DuCaP seeded together with CAFs) were identified by Illumina microarray profiling. Real-time PCR, Western blotting, immunohistochemistry and cell viability assays in 2D and 3D culture were performed to validate the expression of selected targets in vitro and in vivo. Cytokine profiling was conducted to analyze CAF-conditioned medium. Gene expression analysis of co-culture spheroids revealed that CAFs induced a significant upregulation of cholesterol and steroid biosynthesis pathways in PCa cells. Cytokine profiling revealed high amounts of pro-inflammatory, pro-migratory and pro-angiogenic factors in the CAF supernatant. In particular, two genes, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (HMGCS2) and aldo-keto reductase family 1 member C3 (AKR1C3), were significantly upregulated in PCa cells upon co-culture with CAFs. Both enzymes were also significantly increased in human PCa compared to benign tissue with AKR1C3 expression even being associated with Gleason score and metastatic status. Inhibiting HMGCS2 and AKR1C3 resulted in significant growth retardation of co-culture spheroids as well as of various castration and enzalutamide resistant cell lines in 2D and 3D culture, underscoring their putative role in PCa. Importantly, dual targeting of cholesterol and steroid biosynthesis with simvastatin, a commonly prescribed cholesterol synthesis inhibitor, and an inhibitor against AKR1C3 had the strongest growth inhibitory effect. From our results we conclude that CAFs induce an upregulation of cholesterol and steroid biosynthesis in PCa cells, driving them into AR targeted therapy resistance. Blocking both pathways with simvastatin and an AKR1C3 inhibitor may therefore be a promising approach to overcome resistances to AR targeted therapies in PCa. Video abstract.

Sections du résumé

BACKGROUND
Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clinical management of patients, also because the molecular mechanisms behind therapy resistance are not yet fully understood. In the present study, we therefore aimed to identify novel targets to intervene with therapy resistance using gene expression analysis of PCa co-culture spheroids where PCa cells are grown in the presence of cancer-associated fibroblasts (CAFs) and which have been previously shown to be a reliable model for antiandrogen resistance.
METHODS
Gene expression changes of co-culture spheroids (LNCaP and DuCaP seeded together with CAFs) were identified by Illumina microarray profiling. Real-time PCR, Western blotting, immunohistochemistry and cell viability assays in 2D and 3D culture were performed to validate the expression of selected targets in vitro and in vivo. Cytokine profiling was conducted to analyze CAF-conditioned medium.
RESULTS
Gene expression analysis of co-culture spheroids revealed that CAFs induced a significant upregulation of cholesterol and steroid biosynthesis pathways in PCa cells. Cytokine profiling revealed high amounts of pro-inflammatory, pro-migratory and pro-angiogenic factors in the CAF supernatant. In particular, two genes, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (HMGCS2) and aldo-keto reductase family 1 member C3 (AKR1C3), were significantly upregulated in PCa cells upon co-culture with CAFs. Both enzymes were also significantly increased in human PCa compared to benign tissue with AKR1C3 expression even being associated with Gleason score and metastatic status. Inhibiting HMGCS2 and AKR1C3 resulted in significant growth retardation of co-culture spheroids as well as of various castration and enzalutamide resistant cell lines in 2D and 3D culture, underscoring their putative role in PCa. Importantly, dual targeting of cholesterol and steroid biosynthesis with simvastatin, a commonly prescribed cholesterol synthesis inhibitor, and an inhibitor against AKR1C3 had the strongest growth inhibitory effect.
CONCLUSIONS
From our results we conclude that CAFs induce an upregulation of cholesterol and steroid biosynthesis in PCa cells, driving them into AR targeted therapy resistance. Blocking both pathways with simvastatin and an AKR1C3 inhibitor may therefore be a promising approach to overcome resistances to AR targeted therapies in PCa. Video abstract.

Identifiants

pubmed: 31980029
doi: 10.1186/s12964-019-0505-5
pii: 10.1186/s12964-019-0505-5
pmc: PMC6979368
doi:

Substances chimiques

AR protein, human 0
Benzamides 0
Culture Media, Conditioned 0
Nitriles 0
Receptors, Androgen 0
Phenylthiohydantoin 2010-15-3
enzalutamide 93T0T9GKNU
Cholesterol 97C5T2UQ7J
Simvastatin AGG2FN16EV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11

Références

Urology. 2011 Jun;77(6):1508.e1-7
pubmed: 21624609
Ther Adv Med Oncol. 2017 May;9(5):307-318
pubmed: 28529548
Curr Mol Biol Rep. 2017;3(4):230-235
pubmed: 29214142
Diagn Pathol. 2014 Feb 26;9:42
pubmed: 24571686
Clin Med Insights Oncol. 2016 Mar 16;10(Suppl 1):1-9
pubmed: 27013902
Cancer Res. 2007 Jul 1;67(13):6238-46
pubmed: 17616681
EMBO J. 2011 May 20;30(13):2719-33
pubmed: 21602788
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13
pubmed: 19887582
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Korean J Urol. 2015 Sep;56(9):630-6
pubmed: 26366275
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8
pubmed: 18957682
Lancet. 2010 Apr 24;375(9724):1437-46
pubmed: 20398925
Oncol Rep. 2014 Dec;32(6):2605-11
pubmed: 25333856
Cell Metab. 2014 Mar 4;19(3):393-406
pubmed: 24606897
Mol Med. 2013 Jan 22;18:1449-55
pubmed: 23196782
PLoS One. 2014 May 19;9(5):e97764
pubmed: 24841113
JAMA Oncol. 2015 Jul;1(4):495-504
pubmed: 26181260
Int J Cancer. 2010 Feb 1;126(3):775-89
pubmed: 19653278
Anticancer Res. 2015 Jan;35(1):413-8
pubmed: 25550581
Cancer Res. 2012 Dec 1;72(23):6142-52
pubmed: 22971343
J Biol Chem. 2011 Jun 10;286(23):20423-30
pubmed: 21502324
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
J Steroid Biochem Mol Biol. 2012 May;130(1-2):7-15
pubmed: 22265960
Clin Genet. 2009 Jan;75(1):19-29
pubmed: 19054015
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29540470
Oncotarget. 2016 Sep 13;7(37):59781-59794
pubmed: 27486973
Br J Cancer. 1999 Sep;81(2):242-51
pubmed: 10496349
Onco Targets Ther. 2016 Nov 29;9:7263-7274
pubmed: 27942220
F1000Res. 2016 Apr 26;5:null
pubmed: 27158462
Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):46-50
pubmed: 27833018
Biochem J. 1999 Mar 15;338 ( Pt 3):569-82
pubmed: 10051425
Science. 1996 May 3;272(5262):629
pubmed: 8614809
Radiology. 2015 Dec;277(3):751-62
pubmed: 26110669
Cancer Res. 2013 Feb 1;73(3):1211-8
pubmed: 23233737
Eur Urol. 2017 Feb;71(2):151-154
pubmed: 27477525
J Biol Chem. 2018 Dec 28;293(52):20123-20136
pubmed: 30401749
Neurotherapeutics. 2008 Jul;5(3):470-80
pubmed: 18625458
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao. 2015 Dec 20;31(12):1261-1266
pubmed: 27175049
Nat Rev Urol. 2014 Dec;11(12):712-6
pubmed: 25224448
Int J Mol Sci. 2016 Sep 01;17(9):
pubmed: 27598125
Carcinogenesis. 2009 Jan;30(1):20-7
pubmed: 18842679
Mol Cell Proteomics. 2013 Jun;12(6):1589-601
pubmed: 23443136
Mol Cancer Ther. 2017 Jan;16(1):35-44
pubmed: 27794047
J Chem Ecol. 2018 Feb;44(2):189-197
pubmed: 29508108
Cancer Res. 2015 Apr 1;75(7):1413-22
pubmed: 25649766
Expert Rev Endocrinol Metab. 2011 May;6(3):483-493
pubmed: 22389648

Auteurs

Hannes Neuwirt (H)

Department of Internal Medicine IV - Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria.

Jan Bouchal (J)

Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic.

Gvantsa Kharaishvili (G)

Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic.

Christian Ploner (C)

Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Karin Jöhrer (K)

Tyrolean Cancer Research Institute, Innsbruck, Austria.
Salzburg Cancer Research Institute, Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria.

Florian Pitterl (F)

Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Anja Weber (A)

Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Helmut Klocker (H)

Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Iris E Eder (IE)

Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. iris.eder@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH